Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Adcetris® for the Treatment of Relapsed or Refractory Hodgkin’s Lymphoma

Drug Name (Brand / Generic)

Adcetris® (brentuximab vedotin)

Company/Licensee

Seattle Genetics and Millennium Pharmaceuticals / Takeda Pharmaceutical

Therapy Class

Antibody-drug conjugate

Current Indications

Refractory or relapsed Hodgkin's lymphoma, anaplastic large cell lymphoma, peripheral T-cell lymphomas

Market Sector

Oncology

Development Status

Approved in the US, Japan, and Europe
Expand

Go Top